跳至主導覽
跳至搜尋
跳過主要內容
國立陽明交通大學研發優勢分析平台 首頁
English
中文
首頁
人員
單位
研究成果
計畫
獎項
活動
貴重儀器
影響
按專業知識、姓名或所屬機構搜尋
查看斯高帕斯 (Scopus) 概要
楊 慕華
教授
腫瘤惡化卓越研究中心
國立陽明交通大學
h-index
h10-index
h5-index
14328
引文
56
h-指數
按照存儲在普爾（Pure）的出版物數量及斯高帕斯（Scopus）引文計算。
6235
引文
36
h-指數
按照存儲在普爾（Pure）的出版物數量及斯高帕斯（Scopus）引文計算。
1195
引文
18
h-指數
按照存儲在普爾（Pure）的出版物數量及斯高帕斯（Scopus）引文計算。
2000
2025
每年研究成果
概覽
指紋
網路
研究成果
(267)
類似的個人檔案
(8)
指紋
查看啟用 Muh-Hwa Yang 的研究主題。這些主題標籤來自此人的作品。共同形成了獨特的指紋。
排序方式
重量
按字母排序
Keyphrases
Head-and-neck Squamous Cell Carcinoma (HNSCC)
100%
Head-and-neck Cancer
90%
Epithelial-mesenchymal Transition
68%
Oral Tongue Squamous Cell Carcinoma (OTSCC)
48%
Cancer Cells
45%
Taiwan
38%
Metastasis
38%
Chemotherapy
34%
Cetuximab
34%
Recurrent Metastatic
33%
Overall Survival
32%
Twist1
32%
Prognostic Factors
30%
Overexpression
29%
Cisplatin
27%
Tumor
26%
In Cancer
24%
Head-and-neck
24%
Cancer Patients
22%
Hypoxia
22%
Colorectal Cancer
22%
Poor Prognosis
21%
Cancer Metastasis
20%
Confidence Interval
20%
National Cohort Study
19%
Hypoxia-inducible factor-1α (HIF-1α)
18%
Tumor Microenvironment
18%
Stem Cells
18%
Angiogenesis
17%
Phase II Study
17%
Gastric Cancer
16%
Diffuse Large B-cell Lymphoma (DLBCL)
16%
Colorectal Cancer Stem Cells
16%
Multivariate Analysis
15%
BMI1
15%
Induction Chemotherapy
15%
Treatment Outcome
15%
Squamous Carcinoma Cells
15%
Non-Hodgkin Lymphoma
14%
Chemoradiotherapy
14%
Squamous Cell Carcinoma of Head
14%
Recurrent or Metastatic
14%
Phase II Trial
14%
Chronic Myeloid Leukemia
14%
Gastric Cancer Patients
14%
Perineural Invasion
14%
Paclitaxel
13%
Distant Metastasis
13%
Radiotherapy
13%
Locally Advanced
12%
Medicine and Dentistry
Head and Neck Squamous Cell Carcinoma
56%
Head and Neck Cancer
42%
Neoplasm
37%
Metastatic Carcinoma
35%
Overall Survival
35%
Mouth Squamous Cell Carcinoma
30%
Prognostic Factor
29%
Squamous Cell Carcinoma
29%
Abdominal Cancer
23%
Cancer Cell
22%
Neck
20%
Chemoradiotherapy
19%
Colorectal Carcinoma
19%
Malignant Neoplasm
16%
Radiation Therapy
16%
Diseases
16%
Mesenchymal-Epithelial Transition
15%
Angiogenesis
15%
Cetuximab
14%
Perineural Invasion
14%
Risk Stratification
13%
Cancer
12%
Snail
12%
Multivariate Analysis
12%
Adjuvant Therapy
12%
Induction Chemotherapy
12%
Immunity
12%
Nasopharynx Carcinoma
11%
Pembrolizumab
11%
Cisplatin
11%
Oral Cancer
11%
Chronic Myelogenous Leukemia
11%
Cohort Analysis
11%
Oral Cavity
10%
Elderly Patient
10%
Hepatocellular Carcinoma
10%
Transoral Laser Microsurgery
10%
Hypopharyngeal Cancer
10%
Squamous Cell Carcinoma Cell
10%
Neck Dissection
10%
Hazard Ratio
10%
Cancer Stem Cell
10%
Primary Tumor
9%
Distant Metastasis
9%
Endothelial Cell
9%
Biological Marker
9%
Survival Rate
8%
Surgery
8%
Transitional Cell Carcinoma
8%
Bone Marrow Transplantation
8%
